The influence of iron loading and iron chelation on the proliferation and telomerase activity of human peripheral blood mononuclear cells

Iranian Journal of Immunology

Volumn 6, Issue 1, 2009, Pages 33-39

  Bagherpour, Bahram ^a   Gharagozloo, Marjan ^a   Moayedi, Behjat ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Desferrioxamine; Iron; Lymphocytes; Silymarin; Telomerase

Indexed keywords

BROXURIDINE; DEFEROXAMINE; FERROUS SULFATE; PHYTOHEMAGGLUTININ; SILYMARIN; TELOMERASE; ANTIANEMIC AGENT; FERROUS ION; IRON; IRON CHELATING AGENT;

ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IRON CHELATION; IRON METABOLISM; LYMPHOCYTE ACTIVATION; MITOSIS INHIBITION; PERIPHERAL BLOOD MONONUCLEAR CELL; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; LYMPHOCYTE; METABOLISM; MONONUCLEAR CELL;

CELL PROLIFERATION; DEFEROXAMINE; FERROUS COMPOUNDS; HEMATINICS; HUMANS; IRON; IRON CHELATING AGENTS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; PHYTOHEMAGGLUTININS; SILYMARIN; TELOMERASE;

EID: 67650376406     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clin. Cancer Res. 2006;12: 6876-6883.
2. Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M. Iron chelator research: past, present, and future. Curr. Med. Chem. 2003;10: 983-995.
3. Lederman HM., Cohen A, Lee JW, Freedman MH, Gelfand EW. Desferrioxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood. 1984; 64:748-753.
4. Dayani PN, Bishop MC, Black K, Zeltzer PM. Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J. Neurooncol. 2004; 67:367-377.
5. Londoño-Vallejo JA. Telomere instability and cancer. Biochimie. 2008;90:73-82.
6. Shawi M, Autexier C. Telomerase, senescence and ageing. Mech Ageing Dev. 2008;129:3-10.
7. Houben JM, Moonen HJ, van Schooten FJ, Hageman GJ. Telomere length assessment: biomarker of chronic oxidative stress? Free Radic Biol Med. 2008 1;44:235-46.
8. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A. 2004;101:17312-5.
9. Gazak R, Walterova D, Kren V. Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem. 2007; 14: 315-338.
10. Borsari M, Gabbi C, Ghelfi F, Grandi R, Saladini M, Severi S et al. Silybin, a new iron-chelating agent. J Inorg Biochem 2001; 85: 123-129.
11. Tenopoulou M, Doulias PT, Barbouti A, Brunk U, Galaris D. Role of compartmentalized redox-active iron in hydrogen perox-ide-induced DNA damage and apoptosis. Biochem J. 2005; 387:703-710.
12. Traore HN, Meyer D. Comparing qualitative and quantitative spectroscopic techniques for the detection of the effect of direct iron loading of mammalian cell cultures. Methods Cell Sci. 2001; 23:175-184.
13. Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol. 2002; 42:267-281.
14. Bowern N, Ramshaw IA, Badenoch-Jones P, Doherty PC. Effect of an iron-chelating agent on lymphocyte proliferation. Aust J Exp Biol Med Sci. 1984;62:743-54.
15. Gharagozloo M, Khoshdel Z, Amirghofran Z. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine. Eur J Pharmacol 2008;589:1-7.
16. Gharagozloo M, Amirghofran Z. Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells. J Cancer Res Clin Oncol. 2007;133:525-32.
17. Alidoost F, Gharagozloo M, Bagherpour B, Jafarian A, Sajjadi SE, Hourfar H et al. Effects of silymarin on the proliferation and glutathione levels of peripheral blood mononuclear cells from beta-thalassemia major patients. Int Immunopharmacol. 2006;6:1305-10.
18. Wilasrusmee C, Kittu, S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S et al. Immunostimulatory effect of Silybum marianum (milk thistle) extract. Med Sci Monit. 2002; 8:BR439-BR443.
19. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res. 1994; 27:105-112.
20. Brown KE, Meleah Mathahs M, Broadhurst KA, Coleman MC, Ridnour LA, Schmidt WN, Spitz DR. Increased hepatic te-lomerase activity in a rat model of iron overload: a role for altered thiol redox state? Free Radic Biol Med. 2007;42:228-35.
21. Galaris D, Pantopoulos K. Oxidative stress and iron homeostasis: mechanistic and health aspects. Crit Rev Clin Lab Sci. 2008;45:1-23.
22. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2002; 27:339-44.
23. Tosato M, Zamboni V, Ferrini A, Cesari M. The aging process and potential interventions to extend life expectancy. Clin Interv Aging. 2007;2:401-12.